Consideration of Capillary Electrophoresis as an Analysis Technique for the Intended Application of Therapeutic Drug Monitoring of Antipsychotics.

Kara Johns
B.Sc Hons (University of Tasmania)

Submitted in fulfilment of the requirements for the Degree of
Doctor of Philosophy

University of Tasmania
Final Submission September 2013
Declaration of Originality
This thesis contains no material which has been accepted for a degree or diploma by the University or any other institution, except by way of background information and duly acknowledged in the thesis, and to the best of my knowledge and belief no material previously published or written by another person except where due acknowledgment is made in the text of the thesis, nor does the thesis contain any material that infringes copyright.

Authority of Access
The publishers of the paper comprising Chapter 2 hold the copyright for that content, and access to the material should be sought from the respective journal. The remaining non published content of the thesis may be made available for loan and limited copying and communication in accordance with the Copyright Act 1968.

Kara Johns
September, 2013
Statement of Co-Authorship

The following people contributed to the publication of the work undertaken within Chapter 2.

Candidate (80%) and Dr Michael Breadmore (10%) contributed to the idea, its formalisation and development. Dr Bruno Raimondo (5%) and Professor Paul Haddad (5%) assisted with refinements and presentation.

Signed:

Dr Michael Breadmore
Supervisor
School of Chemistry
University of Tasmania

Prof. Allen Canty
Head of School
School of Chemistry
University of Tasmania

September, 2013.
**Ethical Conduct**

The research associated with this thesis abides by the international and Australian codes on human and animal experimentation, the guidelines by the Australian Government's office of the Gene Technology Regulator and the rulings of the Safety, Ethics and Institutional Biosafety committee of the University.

Kara Johns

September, 2013.
Acknowledgements

I’d like to acknowledge the people that contributed academically to the completion of this thesis: my supervisors Dr Michael Breadmore, Dr Bruno Raimondo and Professor Paul Hadded; my fellow PhD students Rowan Henderson, Jessica Gathercole, David Schaller, Ryan Nai, Dr Adam James, Elijah Marshall and Dr Mohamed Dawood, and additional supportive academics Associate Professor Libby Roughead, Professor John Miners, Dr Tom Polasek, Dr Doug McLean and Dr Jill Swartz.

In addition, I’d like to acknowledge the people who contributed to the completion of this thesis through advice, moral support, and encouragement: my dear friends Katrina Munting, Danny Munting, Matthew Samarim, Junann Whish-Wilson, Joseph Bruno, and my family Marcia, Leo, Michael, Charlie and Matilda Johns.

The work presented within this thesis was completed with passion for what the developed methods may actually provide to people dealing with schizophrenia within our communities. As we break the negative stigma and improve the treatment options, there is hope that people directly and indirectly affected by mental illness may be able to fulfil their lives in the way they had always wished.
# Table of Contents

Declaration of Originality ........................................................................................................ II
Authority of Access ................................................................................................................. II
Statement of Co-Authorship ..................................................................................................... III
Ethical Conduct ...................................................................................................................... IV
Acknowledgements ............................................................................................................... V
Table of Contents .................................................................................................................. VI
Abstract ................................................................................................................................... IX
Publications and Presentations .............................................................................................. XI

## Chapter One: Introduction ................................................................................................. 1.1

### 1.1 Mental Illness .............................................................................................................. 1.1

### 1.2 Schizophrenia ............................................................................................................. 1.1

### 1.3 Antipsychotics ............................................................................................................ 1.4

### 1.4 Side Effects of Antipsychotics .................................................................................. 1.5

### 1.5 Maximising the Therapeutic Effects of Antipsychotics ............................................. 1.6

### 1.6 Therapeutic Drug Monitoring (TDM) of Antipsychotics ........................................... 1.7

### 1.7 Current Limitations of TDM of Antipsychotics ......................................................... 1.8

### 1.8 Possible Improvements in TDM of Antipsychotics .................................................... 1.9

### 1.9 Capillary Electrophoresis (CE) .................................................................................. 1.10

### 1.10 Analysis of Antipsychotics by CE .......................................................................... 1.12

### 1.11 General Aim of Thesis ............................................................................................ 1.14

### 1.12 Chapter One References ........................................................................................... 1.16

## Chapter Two: Compliance Monitoring of Antipsychotics: a Versatile Capillary Electrophoresis Method ............................................................................................................. 2.1

### 2.1 Compliance Monitoring of Antipsychotics ................................................................. 2.1

#### 2.1.1 What is compliance? ............................................................................................ 2.1

#### 2.1.2 What are the implications of non-compliance to antipsychotic therapy? .......... 2.1

#### 2.1.3 How serious a problem is non-compliance to antipsychotic therapy? .......... 2.2

#### 2.1.4 Compliance monitoring within clinical care ......................................................... 2.3

#### 2.1.5 How is monitoring of compliance achieved? ....................................................... 2.4

### 2.2 Capillary Electrophoresis for Compliance Monitoring ............................................. 2.7

#### 2.2.1 Introduction ......................................................................................................... 2.7

#### 2.3 Experimental ............................................................................................................ 2.12

##### 2.3.1 Chemicals ........................................................................................................... 2.12

##### 2.3.2 Apparatus ........................................................................................................... 2.12

##### 2.3.3 Preparation of standard solutions ..................................................................... 2.12

##### 2.3.4 Peakmaster settings ......................................................................................... 2.13

##### 2.3.5 Capillary electrophoresis conditions ............................................................... 2.13

#### 2.4 Results and Discussion ............................................................................................ 2.13

##### 2.4.1 Determination of Physical Constants ............................................................... 2.13

##### 2.4.2 Multivariate optimisation .................................................................................. 2.16

##### 2.4.3 Identification of optimal BGE composition ....................................................... 2.16

##### 2.4.4 Comparison of simulated and experimental results ........................................... 2.21

##### 2.4.5 Identification of a suitable CE method for compliance monitoring of antipsychotics ............................................................................................................. 2.24

### 2.5 Conclusion .................................................................................................................. 2.26

### 2.6 Chapter Two References ............................................................................................ 2.27

---

Page VI
Chapter Three: Application of the Developed Capillary Electrophoresis Separation of 17 antipsychotics.

3.1 Introduction ..................................................................................................................... 3.1
3.1.1 Aim ............................................................................................................................. 3.3
3.2 Experimental .................................................................................................................... 3.4
3.2.1 Chemicals ................................................................................................................... 3.4
3.2.2 Apparatus .................................................................................................................. 3.4
3.2.3 Preparation of standard solutions ................................................................................ 3.4
3.2.4 Capillary electrophoresis conditions ............................................................................. 3.5
3.2.5 Validation ................................................................................................................... 3.5
3.2.6 Sample pre-treatment procedures ................................................................................ 3.6
3.3 Results and Discussion ...................................................................................................... 3.8
3.3.1 Further development of the method ............................................................................ 3.8
3.3.2 Validation of the method ........................................................................................... 3.10
3.3.3 Application to different sample matrices ..................................................................... 3.19
3.4 Concluding Remarks ........................................................................................................ 3.31
3.5 Chapter Three References .............................................................................................. 3.32

Chapter Four: Adaptation of the Peakmaster optimised method to capillary electrophoresis—mass spectrometry (CEMS).

4.1 Introduction ....................................................................................................................... 4.1
4.1.1 Why adapt the method to CEMS? ............................................................................. 4.1
4.1.2 Prior developed CE-MS methods for Antipsychotics ...................................................... 4.6
4.2 Experimental ..................................................................................................................... 4.9
4.2.1 Chemicals ................................................................................................................... 4.9
4.2.2 Apparatus .................................................................................................................. 4.9
4.2.3 Preparation of standard solutions ................................................................................ 4.10
4.2.4 Capillary electrophoresis Mass spectrometry conditions ............................................ 4.10
4.3 Results and Discussion ................................................................................................... 4.12
4.3.1 Converting the CE method for suitability to CEMS....................................................... 4.12
4.3.2 Optimisation of the CE-ESI-MS parameters ............................................................... 4.13
5.3.3. Assessment of other CE-MS parameters ................................................................. 4.18
5.3.4 Applicability of the developed CE-MS method ......................................................... 4.20
5.3.5 Evaluation of the CE-MS method of antipsychotics ................................................... 4.24
4.4 Concluding comments .................................................................................................... 4.25
4.5 Chapter Four References ............................................................................................... 4.25
Chapter 5: Transition to Therapeutic Drug Monitoring (TDM) Specific Methods

5.1 General Introduction

5.1.1 What constitutes an ideal TDM method?

5.1.2 Current TDM methods for Antipsychotics

5.2 Experimental

5.2.1 Chemicals

5.2.2 Apparatus

5.2.3 Standard preparation

5.2.4 Capillary electrophoresis conditions

5.2.5 CE-MS conditions

5.2.6 Biological Sample Collection

5.3 TDM of Aripiprazole

5.3.1 Introduction

5.3.2 Results and Discussion of the developed Aripiprazole method

5.3.3 Summary of Aripiprazole work

5.4 TDM method for Five Antipsychotics using CE

5.4.1 Introduction

5.4.2 Results and Discussion of the group antipsychotic method

5.4.3 Summary

5.5 Conclusions

5.6 Chapter Five References

Chapter 6: Conclusions and future directions

6.1 Recapitulating the aim

6.2 Evaluation of CE within the domain of TDM of antipsychotics

6.3 Future direction

6.4 Final conclusion

6.5 Chapter Six References
Abstract

The use of therapeutic drug monitoring (TDM) when prescribing antipsychotics is not yet considered a routine care procedure, despite evidence and opinion regarding its benefit. Amongst the arguments against the inclusion of TDM, are the many logistical deficiencies that prevent the TDM service from being as optimal as warranted. It has been identified that improvements within the service being offered for TDM may result in improvements with the overall TDM practice; which may result in an increase usage. It was recognised that altering the analysis technique to a faster, more versatile process, may be impacting on the overall service that could be offered and thus improve the holistic practice of TDM of antipsychotics. Capillary electrophoresis (CE) was chosen for consideration as an alternate analysis technique, primarily due to the known ability of this technique to achieve fast separations of structurally similar compounds and its ability to be readily implemented in small potentially portable lab-on-a-chip devices. It was therefore the aim of this thesis to develop and consider CE methods for the analysis of antipsychotics for the intended application of TDM.

The development of CE methods was performed in a step-wise manner, through an understanding of the applications use. The first method developed was aimed at a secondary application of TDM of compliance monitoring and achieved through an extensive examination of a multivariate optimisation of separation parameters using the modelling software known as Peakmaster. Through this work a set of parameters was identified that allowed for the separation of 17 antipsychotics within 5 minutes. The optimal method was subsequently validated for evaluation and found to be analytical suitable for consideration within a compliance monitoring setting. In addition, the developed separation was successfully adapted for compatibility with a mass spectrometer detector...
(CE-MS), however this was not considered appropriate for clinical application at this stage due to instrumental weakness observed during this work.

The second stage of focus was to progress the method development specifically towards TDM appropriate applications. This was achieved by developing the first separation for aripiprazole and both main metabolites. Here a separation was achieved for three structurally similar compounds within nine minutes and found to be ideal for the intended application of TDM. Having successfully developed a CE method suitable for TDM, the final method was developed with the aim of incorporating the two positive elements of the prior two methods: many compounds within one method and achieve separation of structurally similar compounds. Consequently a method was developed incorporating five popularly prescribed antipsychotics and metabolites, resulting in a separation of 13 compounds within eight minutes.

The methods developed and presented within this thesis were considered suitable for the intended application of TDM. Due to the speed and resolution achieved within the separations, it was foreseeable that the implementation of these methods would have the potential of improving the versatility of the TDM service and therefore potentially improve the usage of TDM for antipsychotics. It was clearly acknowledged that further assessment would be necessary (such as tandem testing) before suggesting these methods be implemented. However the work here supports the idea of changing the analytical technique employed for the process of TDM of antipsychotics to CE, as a modification that would allow for improvements to the overall service delivered.
Publications and Presentations

Publications


Presentations

IATDMCT 10th International congress
Nice, France, September 2007
Poster entitled: Monitoring of Anti-Psychotics: improving the analytical methodology for compliance and therapeutic drug monitoring with capillary electrophoresis-mass spectrometry.

19th International Symposium on Pharmaceutical and Biomedical Analysis (PBA)
Gdansk, Poland, June 2008
Poster entitled: Computer aided multivariate optimization of a capillary electrophoresis separation of 17 anti-psychotics for compliance monitoring.